USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
X
Address:
2810 N COMMERCE PKY
MIRAMAR, FL
Phone:
N/A
URL:
N/A
EIN:
50523659
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,101,511.00 9
SBIR Phase II $6,284,086.00 5

Award List:

T-cell receptor based therapeutics for cytomegalovirus

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by investigator): The goal of these studies is to evaluate the feasibility of using a T-cell receptor based fusion protein as a targeting agent for therapies for CMV, which remains a major cause of morbidity and mortality inimmunocompromised patients. For these studies a TCR… More

NOVEL DRUG DISCOVERY FOR MULTIPLE SCLEROSIS

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this project is to develop small molecule inhibitors of TCR:MHC class II-peptide interactions for the treatment of multiple sclerosis (MS). The strong genetic association between specific MHC class ll alleles, such as HLA-DR2… More

Bifunctional T cell receptor based immunotherapeutics

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$1,112,023.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of these studies is to further pre-clinical development of a soluble three-domain single chain T-cell receptor IL-2 fusion protein (264scTCR/IL-2). This T-cell receptor, which recognizes an unmutated peptide epitope of the human tumor suppressor protein,… More

Soluble T-cell receptor based tumor screening reagents

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this research is to demonstrate proof-of-principle for using a T-cell receptor (TCR)-based fusion protein as a staining reagent for human tumors. The TCR portion of this fusion protein is specific for an unmutated p53 peptide presented in the context… More

Tissue Factor Antagonists for ALI/ARDS

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$110,542.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to develop an anti-tissue factor antibody, Sunol-cH36, as a treatment for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). The association between coagulation and inflammation has been well established and… More

Transgenic Plant Technology for Producing Therapeutic Recombinant Antibodies

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$100,001.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The need to develop novel, cost effective manufacturing processes to produce therapeutic antibodies commercially will continue to be of considerable and growing interest to biopharmaceutical and medical industries. The long-term objectives related to this… More

NOVEL DRUG DISCOVERY FOR RHEUMATOID ARTHRITIS

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$112,209.00
Agency:
HHS
Principal Investigator:
Peter R. Rhode
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this project is to develop small molecule inhibitors of MHC class II activity for the treatment of rheumatoid arthritis (RA). The strong genetic association between specific MHC class II alleles, such as HLA-DR molecules containing the… More

Transgenic Plant Technology for Producing Therapeutic Recombinant Antibodies

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$1,234,949.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is an urgent need to develop novel, cost-effective manufacturing processes to produce therapeutic antibodies commercially in order to reduce the high manufacturing expenses as well as to address the potential for limited manufacturing capacity. The… More

Tissue Factor Antagonists for ALI/ARDS

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$2,079,846.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to develop an anti-tissue factor antibody, Sunol-cH36, as a treatment for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). The association between coagulation and inflammation has been well established and… More

Bifunctional T cell receptor based immunotherapeutics

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$2,969,291.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this project is to develop a tumor-targeted TCR-IL2 fusion protein, ALT-801, as an immunotherapeutic for treatment of p53-positive cancers. The TCR portion of this fusion protein is specific f or a peptide derived from the… More

Creation of TCR-based Immunotherapeutic Targeting HIV-1

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$164,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to create immunotherapeutics based on two high-affinity, HIV-specific, soluble T cell receptors (TCRs) as targeting molecules for HIV-infected cells. These human-derived TCRs were selected b ased on their ability to recognize HIV… More

Soluble TCR-IL15 Fusions as Targeted Therapeutics for Cancer

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$202,736.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this proposal is to develop tumor-targeted TCR-IL15 fusion proteins as immunotherapeutics for treating cancers. Previous proof-of-concept studies with TCR-IL2 and TCR-IgG1 fusion proteins in m ouse tumor efficacy models demonstrated the… More

X

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
X

X

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
X